Boosting regulatory T-cell function with the humanized CD4-specific humanized monoclonal antibody Tregalizumab (BT-061)

Immunology and Cell Biology

Volumn 93, Issue 4, 2015, Pages 321-322

  Humblet Baron, Stéphanie ^a   Baron, Frédéric ^a,b  

^a UNIVERSITY OF LEUVEN   (Belgium)

^b UNIVERSITY OF LIÈGE   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIBODY; CD4 ANTIGEN; INTERLEUKIN 2 RECEPTOR; METHOTREXATE; OKT 3; TRANSCRIPTION FACTOR FOXP3; TREGALIZUMAB; EPITOPE; IMMUNOSUPPRESSIVE AGENT; MONOCLONAL ANTIBODY;

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; AUTOIMMUNE DISEASE; CD4+ T LYMPHOCYTE; CELL FUNCTION; CELL SURFACE; GRAFT VERSUS HOST REACTION; HUMAN; NONHUMAN; NOTE; PHASE 2 CLINICAL TRIAL (TOPIC); REGULATORY T LYMPHOCYTE; IMMUNOLOGY; METABOLISM; T LYMPHOCYTE SUBPOPULATION;

ANTIBODIES, MONOCLONAL; ANTIGENS, CD4; EPITOPES, B-LYMPHOCYTE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; T-LYMPHOCYTE SUBSETS; T-LYMPHOCYTES, REGULATORY;

EID: 84928208498     PISSN: 08189641     EISSN: 14401711     Source Type: Journal    
DOI: 10.1038/icb.2014.120     Document Type: Note

References (14)

1. Josefowicz SZ, Lu LF, Rudensky AY. Regulatory T cells: mechanisms of differentiation and function. Annu Rev Immunol 2012; 30: 531-564.
2. Liston A, Gray DH. Homeostatic control of regulatory T cell diversity. Nature Reviews Immunol 2014; 14: 154-165.
3. Sakaguchi S, Sakaguchi N, Asano M, Itoh M, Toda M. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol 1995; 155: 1151-1164.
4. Miyara M, Ito Y, Sakaguchi S. TREG-cell therapies for autoimmune rheumatic diseases. Nat Rev Rheumatol 2014; 10: 543-551.
5. Saadoun D, Rosenzwajg M, Joly F, Six A, Carrat F, Thibault V et al. Regulatory T-cell responses to low-dose interleukin-2 in HCV-induced vasculitis. New England J Med 2011; 365: 2067-2077.
6. Socie G, Ritz J. Current issues in chronic graft-versus-host disease. Blood 2014; 124: 374-384.
7. Matsuoka K, Koreth J, Kim HT, Bascug G, McDonough S, Kawano Y et al. Low-dose interleukin-2 therapy restores regulatory T cell homeostasis in patients with chronic graft-versus-host disease. Sci Transl Med 2013; 5: 179ra43.
8. Martelli MF, Di Ianni M, Ruggeri L, Falzetti F, Carotti A, Terenzi A et al. HLA-haploidentical transplantation with regulatory and conventional T cell adoptive immunotherapy prevents acute leukemia relapse. Blood 2014; 124: 638-644.
9. Marek-Trzonkowska N, Mysliwiec M, Dobyszuk A, Grabowska M, Derkowska I, Juscinska J et al. Therapy of type 1 diabetes with CD4(+)CD25(high)CD127-regulatory T cells prolongs survival of pancreatic islets-results of one year follow-up. Clin Immunol 2014; 153: 23-30.
10. Becker C, Bopp T, Jonuleit H. Boosting regulatory T cell function by CD4 stimulation enters the clinic. Front immunol 2012; 3: 164.
11. Mayer CT, Tian L, Hesse C, Kuhl AA, Swallow M, Kruse F et al. Anti-CD4 treatment inhibits autoimmunity in scurfy mice through the attenuation of co-stimulatory signals. J Autoimmun 2014; 50: 23-32.
12. Hellling B, König M, Dälken B, Engling A, Krömer W, Heim K et al. A specific CD4 epitope bound by tregalizumab mediates activation of regulatory T cells by a unique signaling pathway. Immunol Cell Biol 2015; 93: 396-405.
13. Levine AG, Arvey A, Jin W, Rudensky AY. Continuous requirement for the TCR in regulatory T cell function. Nat Immunol 2014; 15: 1070-1078.
14. Becker C, Taube C, Bopp T, Becker C, Michel K, Kubach J et al. Protection from graft-versus-host disease by HIV-1 envelope protein gp120-mediated activation of human CD4+CD25+ regulatory T cells. Blood 2009; 114: 1263-1269.